

# Contents

---

<b>List of figures</b>	<b>i-viii</b>
<b>List of tables</b>	<b>ix-xiv</b>
<b>List of abbreviations and symbols</b>	<b>xv-xvii</b>
<b>Preface</b>	<b>xviii-xix</b>
<b>1. Introduction</b>	<b>01-10</b>
<b>2. Literature review</b>	<b>11-81</b>
2.1 Objective related background	11
2.2 Disease related background	18
2.3 Formulation related background	24
2.3.1 Cocrystals (CoCs)	26
2.3.2 Ternary cyclodextrin (CD) complexes	37
2.3.3 Drug nanocrystals (NCs)	49
2.4 Formulation ingredients specific review	60
2.4.1 Drug profile	60
2.4.2 Excipients' profile	70
<b>3. Objective and Plan of work</b>	<b>82-88</b>
<b>4. Materials – Chemicals, Equipments, Software and Animals</b>	<b>89-94</b>
4.1 Materials	89
4.1.1 Chemicals	89
4.1.2 Equipments	91
4.1.3 Software	93
4.1.4 Animals	93
<b>5. Preparation and characterization of ezetimibe cocrystals</b>	<b>95-172</b>
5.1 Introduction	96
5.2 Materials	99
5.3 Methods	99
5.3.1 Optimization of composition of ezetimibe – nicotinic acid (Eze-NA) and ezetimibe – nicotinamide (Eze-ND) cocrystals (CoCs)	99
5.3.2 Preparation and characterization of Eze-NA and Eze-ND CoCs	103
5.4 Results and discussion	121
5.4.1 Optimization of composition of Eze-NA and Eze-ND CoCs	121
5.4.2 Characterization of Eze-NA and Eze-ND CoCs	130
5.5 Summary	169
5.6 Graphical summary	171

<b>6. Preparation and characterization of ezetimibe ternary cyclodextrin complexes</b>	<b>173-229</b>
6.1 Introduction	174
6.2 Materials	178
6.3 Methods	179
6.3.1 Optimization of the composition of binary Ezetimibe - Hydroxypropyl- $\beta$ -cyclodextrin (E-CD) complex and ternary, Ezetimibe - Hydroxypropyl- $\beta$ -cyclodextrin - D- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate (E-CD-TPGS) and Ezetimibe - hydroxypropyl- $\beta$ -cyclodextrin - L-ascorbic acid-2-glucoside (E-CD-AA2G) inclusion complexes	179
6.3.2 Preparation and characterization of solid inclusion complexes	181
6.4 Results and discussion	187
6.4.1 Optimization of the composition of binary E-CD complex and ternary, E-CD-TPGS and E-CD-AA2G inclusion complexes	187
6.4.2 Characterization of solid inclusion complexes	196
6.5 Summary	227
6.6 Graphical summary	228
<b>7. Preparation and characterization of ezetimibe drug nanocrystals</b>	<b>230-343</b>
7.1 Introduction	231
7.2 Materials	234
7.3 Methods	234
7.3.1 Optimization of preparation of L-ascorbic acid-2-glucoside drug nanocrystals (ANCs) and D- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate drug nanocrystals (TNCs) for confirmatory trials – application of experimental designs	234
7.3.2 Preparation and characterization of ANCs and TNCs	250
7.4 Results and discussion	257
7.4.1 Optimization of preparation of ANCs and TNCs for confirmatory trials – application of experimental designs	257
7.4.2 Characterization of the optimized ANCs and TNCs prepared as per confirmatory trials	309
7.5 Summary	340
7.6 Graphical summary	341
<b>8. Evaluating the effect of different formulation approaches on the <i>in-vitro</i> and <i>in-vivo</i> performance of ezetimibe</b>	<b>344-412</b>
8.1 Introduction	345
8.2 Methods	347
8.2.1 Saturation aqueous solubility studies	347
8.2.2 Dissolution	347
8.2.3 Stability	348
8.2.4 <i>In-vivo</i> preclinical pharmacokinetic study	349

8.2.5	<i>In-vivo</i> preclinical pharmacodynamic study	350
8.2.6	Statistical analysis	357
8.3	Results and discussion	357
8.3.1	Aqueous solubility and dissolution	357
8.3.2	Stability	366
8.3.3	<i>In-vivo</i> preclinical pharmacokinetic study	370
8.3.4	<i>In-vivo</i> preclinical pharmacodynamic study	375
8.4	Summary	410
<b>9.</b>	<b>Conclusions</b>	<b>413-417</b>
<b>10.</b>	<b>Bibliography</b>	<b>418-437</b>
	List of papers published/presented	
	Reprints of published papers	
	Personal profile of the candidate	